These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20504085)

  • 21. Is the modified natural in vitro fertilization cycle justified in patients with "genuine" poor response to controlled ovarian hyperstimulation?
    Kedem A; Tsur A; Haas J; Yerushalmi GM; Hourvitz A; Machtinger R; Orvieto R
    Fertil Steril; 2014 Jun; 101(6):1624-8. PubMed ID: 24680364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-dose GnRH antagonist protocol is as effective as the long GnRH agonist protocol in unselected patients undergoing in vitro fertilization and embryo transfer.
    Huang SY; Huang HY; Yu HT; Wang HS; Chen CK; Lee CL; Soong YK
    Taiwan J Obstet Gynecol; 2011 Dec; 50(4):432-5. PubMed ID: 22212313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized trial of microdose leuprolide acetate protocol versus luteal phase ganirelix protocol in predicted poor responders.
    DiLuigi AJ; Engmann L; Schmidt DW; Benadiva CA; Nulsen JC
    Fertil Steril; 2011 Jun; 95(8):2531-3. PubMed ID: 21324455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Menstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists.
    Kolibianakis EM; Papanikolaou EG; Camus M; Tournaye H; Van Steirteghem AC; Devroey P
    Hum Reprod; 2006 Apr; 21(4):1012-7. PubMed ID: 16339166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minimal stimulation protocol using letrozole versus microdose flare up GnRH agonist protocol in women with poor ovarian response undergoing ICSI.
    Mohsen IA; El Din RE
    Gynecol Endocrinol; 2013 Feb; 29(2):105-8. PubMed ID: 23134528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study.
    König TE; van der Houwen LE; Overbeek A; Hendriks ML; Beutler-Beemsterboer SN; Kuchenbecker WK; Renckens CN; Bernardus RE; Schats R; Homburg R; Hompes PG; Lambalk CB
    Hum Reprod; 2013 Oct; 28(10):2804-12. PubMed ID: 23838159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
    Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
    Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ovulatory follicle dysfunction in lactating dairy cows after treatment with Folltropin-V at the onset of luteolysis.
    Giordano JO; Edwards JL; Di Croce FA; Roper D; Rohrbach NR; Saxton AM; Schuenemann GM; Prado TM; Schrick FN
    Theriogenology; 2013 May; 79(8):1210-7. PubMed ID: 23534994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gonadotrophin-releasing hormone-antagonist luteolysis during the preceding mid-luteal phase is a feasible protocol in ovarian hyperstimulation before in vitro fertilization.
    Fridén BE; Nilsson L
    Acta Obstet Gynecol Scand; 2005 Aug; 84(8):812-6. PubMed ID: 16026411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
    Griesinger G; Schultze-Mosgau A; Dafopoulos K; Schroeder A; Schroer A; von Otte S; Hornung D; Diedrich K; Felberbaum R
    Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists.
    Kolibianakis EM; Schultze-Mosgau A; Schroer A; van Steirteghem A; Devroey P; Diedrich K; Griesinger G
    Hum Reprod; 2005 Oct; 20(10):2887-92. PubMed ID: 15979994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can 200 IU of hCG replace recombinant FSH in the late follicular phase in a GnRH-antagonist cycle? A pilot study.
    Blockeel C; De Vos M; Verpoest W; Stoop D; Haentjens P; Devroey P
    Hum Reprod; 2009 Nov; 24(11):2910-6. PubMed ID: 19617207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF.
    Kolibianakis EM; Zikopoulos K; Schiettecatte J; Smitz J; Tournaye H; Camus M; Van Steirteghem AC; Devroey P
    Hum Reprod; 2004 Nov; 19(11):2490-6. PubMed ID: 15319383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial.
    Cheung LP; Lam PM; Lok IH; Chiu TT; Yeung SY; Tjer CC; Haines CJ
    Hum Reprod; 2005 Mar; 20(3):616-21. PubMed ID: 15608037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GnRH antagonist in older IVF patients. Retrieval rates and clinical outcome.
    Chang PL; Zeitoun KM; Chan LK; Thornton MH; Sauer MV
    J Reprod Med; 2002 Apr; 47(4):253-8. PubMed ID: 12012875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alternate day and daily administration of GnRH antagonist may prevent premature luteinization to a similar extent during FSH treatment.
    Messinis IE; Loutradis D; Domali E; Kotsovassilis CP; Papastergiopoulou L; Kallitsaris A; Drakakis P; Dafopoulos K; Milingos S
    Hum Reprod; 2005 Nov; 20(11):3192-7. PubMed ID: 16037104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of clomiphene citrate during ovarian stimulation on the luteal phase after GnRH agonist trigger.
    Derksen L; Tournaye H; Stoop D; Van Vaerenbergh I; Bourgain C; Polyzos NP; Haentjens P; Blockeel C
    Reprod Biomed Online; 2014 Mar; 28(3):359-68. PubMed ID: 24456700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group.
    Hum Reprod; 1998 Nov; 13(11):3023-31. PubMed ID: 9853849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.